676596-50-2

Upstream product

• 225517-15-7 (S)-N^α-(tert-butyloxycarbonyl)-4-hydroxyphenylglycine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 77-92-9 citric acid 
• 848498-04-4 (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-oxocyclohexyl)acetate 
• 684283-02-1 methyl 2-(benzyloxycarbonylamino)-2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate 
• 873581-24-9 methyl (2S)-{[(benzyloxy)carbonyl]amino}(1,4-dioxaspiro[4.5]dec-8-yl)ethanoate 
• 873581-25-0 C₁₆H₂₇NO₆ 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 848498-04-4 (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-oxocyclohexyl)acetate 
• 336870-02-1 C₁₃H₂₃NO₅ 
• 394735-63-8 (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4,4-difluorocyclohexyl)acetate 
• 815581-00-1 [(S)-1-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)-2-((S)-3-fluoro-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid benzyl ester 
• 815580-99-5 [(S)-1-(3-Bromo-4-oxo-cyclohexyl)-2-((S)-3-fluoro-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid benzyl ester 
• 676517-02-5 [(S)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-2-oxo-1-(4-oxo-cyclohexyl)-ethyl]-carbamic acid benzyl ester 
• 676517-03-6 [(S)-1-(3-Bromo-4-oxo-cyclohexyl)-2-((S)-3-fluoro-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 676517-00-3 benzyl [(1S)-2-oxo-1-(4-oxocyclohexyl)-2-pyrrolidinylethyl]carbamate 
• 676517-01-4 [(S)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-2-oxo-1-(4-oxo-cyclohexyl)-ethyl]-carbamic acid tert-butyl ester 
• 816421-81-5 [(S)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-1-(4-hydroxy-cyclohexyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 676516-99-7 [2-oxo-1-(4-oxo-cyclohexyl)-2-pyrrolidin-1-yl-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17

The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

AZAINDOLE INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and R9 are as described herein.

INHIBITORS OF IAP

The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4', R5, R5'/

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1 - M - U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3', R4, R4' and R5, are as described herein.

IMIDAZOPYRIDINE INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X1, X2, Y, Z R1, R2, R3, R3', R4, R4', R5, R6, R6' and n are as described herein.